MS COMPASS
+
Pears Health Cyber’s MS Compass+
mobile application at the eyeforpharma Barcelona Awards
PLAY VIDEO
The project was selected from hundreds of initiatives from Europe, Middle East, Africa and Asia/Pac. It was shortlisted for the category „Most Valuable Patient Initiative or Service.
CHECK OUT THE VIDEO
FOR PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH COPAXONE,
A PRODUCT MARKETED BY TEVA.
The drug is administered daily or three times a week by injection and it is necessary to vary the application areas on the body. Areas or individual locations can be set in the app where injection is prohibited. These can be cases, where the patient has had an injury or the injection in these places is extremely painful for him/her. The user can also set the depth of injection for each application zone, the time for injection and the amount of injections received from the physician.
Intelligent mobile
personal assistant
Personalized setting of injection sites
The user can also set the depth of injection
The MS Compass+ reminds daily at given time the moment for injection and advises the patient injection site for the current day. Upon confirmation of having applied the injection, the patient can, in the event of adverse skin reactions, take a picture and store it with a text note to the app and e-mail this data to the physician.
MS Compass+ also monitors the remaining number of injections and keeps statistics on the use of the drug. The application includes an instructional video, recommendations for lifestyle, myths and superstitions about the disease, patient leaflet and tips and tricks for MS patients.
MS COMPASS+ IS DESIGNED FOR IPADS AND IPHONES RUNNING UNDER THE IOS OPERATING SYSTEM
Android devices support the app as well. The app can be easily downloaded from App Store / Google Play; it is free of charge. There are Czech, Slovak, Finnish and Swedish versions available. To run the app you must enter the access code which the patient will have been given by their doctor.
The MS Compass+ mobile app was launched in the Czech Republic in January 2015. It is now gradually being adopted by patients in other European countries as well.
Package leaflet: Information for the user
COPAXONE 20 mg/ml
Developed by
Copyright © 1999 - 2016